KSR1 antibodies have been instrumental in elucidating its role in oncogenic transformation:
Melanoma: CRISPR/Cas9-mediated KSR1 knockout in BRAF-mutant melanoma cells reduced proliferation, increased apoptosis, and impaired 3D tumor growth .
Colorectal Cancer: KSR1 depletion decreased EPSTI1 protein levels, a marker of epithelial-mesenchymal transition, via ERK-dependent translational regulation .
Small-Cell Lung Carcinoma: KSR1 knockout reduced tumor-initiating cell frequency and sensitized cells to cisplatin .
NK/T Cells: KSR1-deficient natural killer (NK) cells showed impaired cytolytic granule polarization and ERK recruitment to immunological synapses .
Inflammatory Bowel Disease: KSR1 deficiency exacerbated colitis in Il10−/− mice by enhancing IFN-γ production in T cells .
KSR1 antibodies validated its necessity for ERK activation post-DNA damage (e.g., UV, mitomycin C). Cells lacking KSR1 failed to re-enter the cell cycle after G2/M arrest .
AF7917: Derived from residues near the C-terminus of human KSR1 (UniProt: Q8IVT5) .
Post-Translational Modifications (PTMs):
KSR1 undergoes phosphorylation, ubiquitination, and acetylation at specific residues (see table below) :
| Residue | PTM Type | Functional Implication |
|---|---|---|
| S406 | Phosphorylation | Linked to MAP3K7/NME1 signaling |
| Y552 | Phosphorylation | Modulates scaffold activity |
| K656, K709 | Acetylation | Regulatory roles in ERK signaling |
WB Specificity: AF7917 detects a 120 kDa band in human and mouse lysates, while ab68483 shows a 110 kDa band in human tissues .
IHC Reliability: ab68483 demonstrated strong nuclear/cytoplasmic staining in cervical carcinoma FFPE sections .
Scaffold vs. Kinase Activity: KSR1 exhibits dual roles as a scaffold and functional kinase, autophosphorylating serine residues and phosphorylating MEK1 to regulate TNF-induced cell survival .
Concentration-Dependent Signaling: Optimal KSR1 expression (14× endogenous levels) maximizes ERK activation and proliferation, while overexpression inhibits signaling .
Therapeutic Potential: KSR1 knockout mice resist Ras-driven tumorigenesis, highlighting its viability as a drug target .